Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction

Moderna raised its 2026 revenue growth forecast to a range of 15% to 25%, up from previous guidance of up to 10%, the company announced. CNBC reported the CEO attributed the higher outlook to newer vaccines gaining traction. The revision applied to full-year 2026 revenue expectations.

• CNBC — Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction
• MarketWatch — Moderna’s stock jumps after biotech raises sales outlook

Next story